Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
University of Colorado Denver · Tufts University · +5 more institutions
Abstract
No abstract available for this paper.
Citation impact
- FWCI
- 17.76
- Percentile
- 100%
- References
- 22
Authors
9- TFTimothy F. FeltesCorresponding
University of Colorado Denver, Tufts University, Nationwide Children's Hospital, Children's Hospital Colorado, The Ohio State University, Mayo Clinic, Tufts Medical Center
- AKAllison K. Cabalka
Tufts University, Children's Hospital Colorado, Nationwide Children's Hospital, Tufts Medical Center, University of Colorado Denver, Mayo Clinic, The Ohio State University
- HCH. Cody Meissner
Children's Hospital Colorado, Tufts University, Nationwide Children's Hospital, Mayo Clinic, Tufts Medical Center, The Ohio State University, University of Colorado Denver
- FMFranco M. Piazza
Mayo Clinic, Tufts University, The Ohio State University, Children's Hospital Colorado, Nationwide Children's Hospital, Tufts Medical Center, University of Colorado Denver
- DADavid A Carlin
Tufts Medical Center, The Ohio State University, Mayo Clinic, Nationwide Children's Hospital, Children's Hospital Colorado, University of Colorado Denver, Tufts University
Topics & keywords
- Palivizumab
- Medicine
- Placebo
- Adverse effect
- Heart disease
- Pediatrics
- Randomized controlled trial
- Respiratory system
- Good health and well-being